ABVX

ABIVAX SA (NASDAQ:ABVX) is a French biotechnology company founded in 2013 and headquartered in Paris. The company went public on the NASDAQ in October 2023, making it a relatively new entrant to the U.S. public markets. ABIVAX focuses on discovering and developing innovative drugs for treating inflammatory diseases, infectious diseases, and cancer. As a clinical-stage biopharmaceutical company, ABIVAX is currently advancing multiple drug candidates through various phases of clinical trials, with its lead compound ABX464 showing promise in treating autoimmune and inflammatory conditions.